Home » Stocks » ORGS

Orgenesis Inc. (ORGS)

Stock Price: $7.17 USD 0.13 (1.85%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 173.20M
Revenue (ttm) 14.43M
Net Income (ttm) -58.78M
Shares Out 22.09M
EPS (ttm) 2.35
PE Ratio 3.05
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $7.17
Previous Close $7.04
Change ($) 0.13
Change (%) 1.85%
Day's Open 7.10
Day's Range 6.80 - 7.23
Day's Volume 150,935
52-Week Range 2.76 - 8.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

GERMANTOWN, Md., March 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gen...

Seeking Alpha - 1 month ago

Orgenesis is a $151m market cap biotech focused on cell and gene therapy technologies. It has a technology, therapeutics, and point of care platform that enables its CGT partners to develop pr...

GlobeNewsWire - 4 months ago

Reports rapid advancement of therapeutic pipeline

GlobeNewsWire - 4 months ago

GERMANTOWN, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene ...

GlobeNewsWire - 4 months ago

Icellator® commercially available for lipotransfer in first two countries with more approvals expected Icellator® commercially available for lipotransfer in first two countries with more appro...

GlobeNewsWire - 5 months ago

Acquisition to support accelerated commercialization of Koligo’s KYSLECEL®,  a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis

GlobeNewsWire - 5 months ago

GERMANTOWN, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and...

GlobeNewsWire - 6 months ago

GERMANTOWN, Md., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and ...

GlobeNewsWire - 7 months ago

Provides update on COVID-19 therapeutic programs

GlobeNewsWire - 7 months ago

GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercializ...

GlobeNewsWire - 8 months ago

GERMANTOWN, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commerciali...

GlobeNewsWire - 8 months ago

GERMANTOWN, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commerciali...

GlobeNewsWire - 8 months ago

GERMANTOWN, Md., June 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercializ...

GlobeNewsWire - 9 months ago

GERMANTOWN, Md., June 01, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercializat...

GlobeNewsWire - 9 months ago

Collaboration project focused on clinical development and validation of Orgenesis’ immune-oncology cell therapies Collaboration project focused on clinical development and validation of Orgene...

GlobeNewsWire - 9 months ago

GERMANTOWN, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercializa...

Benzinga - 9 months ago

Orgenesis (NASDAQ: ORGS) shares are trading higher on Wednesday. The company announced a cell-based vaccine platform targeting COVID-19 and other existing and emerging viral diseases.

GlobeNewsWire - 9 months ago

Initiating a novel program targeting the virus and virus infected cells, using whole cell-based vaccines Initiating a novel program targeting the virus and virus infected cells, using whole ce...

GlobeNewsWire - 9 months ago

Cash and cash equivalents of $107.1 million as of March 31, 2020 Cash and cash equivalents of $107.1 million as of March 31, 2020

GlobeNewsWire - 10 months ago

GERMANTOWN, Md., April 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercial...

GlobeNewsWire - 10 months ago

GERMANTOWN, Md., April 27, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercializa...

Seeking Alpha - 10 months ago

Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: PSTI, TDOC
GlobeNewsWire - 10 months ago

Strategy to combine ranpirnase antiviral platform with Bioxome™ technology Strategy to combine ranpirnase antiviral platform with Bioxome™ technology

GlobeNewsWire - 10 months ago

JV to utilize RevaTis’s patented technique to obtain mdMSCs through a minimally invasive muscle biopsy and leverage mdMSC manufacturing capability

GlobeNewsWire - 11 months ago

Patented process results in uniform, scalable production and ability to deliver cell cargo similar to natural exosomes/EVs Patented process results in uniform, scalable production and ability ...

GlobeNewsWire - 11 months ago

GERMANTOWN, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, acceler...

GlobeNewsWire - 1 year ago

GERMANTOWN, Md., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”)...

GlobeNewsWire - 1 year ago

GERMANTOWN, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masth...

GlobeNewsWire - 1 year ago

GERMANTOWN, Md., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CD...

GlobeNewsWire - 1 year ago

First collaboration project focused on developing and commercializing lentiviral manufacturing system First collaboration project focused on developing and commercializing lentiviral manufactu...

GlobeNewsWire - 1 year ago

Milestone Payment from Great Point Partners Marks Second and Final Payment of its $25 Million Planned Investment Milestone Payment from Great Point Partners Marks Second and Final Payment of i...

GlobeNewsWire - 1 year ago

Partnership to enable HYGEIA’s hospital network to develop and deliver onsite cell and gene therapies to patients Partnership to enable HYGEIA’s hospital network to develop and deliver onsite ...

GlobeNewsWire - 1 year ago

GERMANTOWN, Md., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDM...

GlobeNewsWire - 1 year ago

GERMANTOWN, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO m...

GlobeNewsWire - 1 year ago

GERMANTOWN, Md., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDM...

GlobeNewsWire - 1 year ago

Generates over $1 million in sales through new POCare platform Generates over $1 million in sales through new POCare platform

GlobeNewsWire - 1 year ago

Appointment adds innovation and optical technology skills to advance cell and gene therapy capabilities Appointment adds innovation and optical technology skills to advance cell and gene thera...

GlobeNewsWire - 1 year ago

Presentation Scheduled for Tuesday, September 10th at 12:35 PM Eastern Time Presentation Scheduled for Tuesday, September 10th at 12:35 PM Eastern Time

Market Watch - 1 year ago

Orgenesis Inc. shares soared 19% in premarket trade Monday, after the U.S.

Zacks Investment Research - 1 year ago

Orgenesis Inc. (ORGS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

About ORGS

Orgenesis offers biotechnology solutions focusing on cell and gene therapies (CGTs). The company's Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on identification of new therapies and leverages its POCare platform to provide a pathway for these therapies to treat patients. Additionally, the company's Network brings together patients, doctors, industry pa... [Read more...]

Industry
Biotechnology
Founded
2008
CEO
Vered Caplan
Employees
309
Stock Exchange
NASDAQ
Ticker Symbol
ORGS
Full Company Profile

Financial Performance

In 2019, Orgenesis's revenue was $33.26 million, an increase of 78.27% compared to the previous year's $18.66 million. Losses were -$24.12 million, 31.9% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Orgenesis is 10.00, which is an increase of 39.47% from the latest price.

Price Target
$10.00
(39.47% upside)